Retatrutide Explained: Trial Results, FDA Filing and the Counterfeit Risk

Retatrutide has become one of the most searched-for drugs that nobody can legally buy. Eli Lilly's once-weekly injection has now posted positive results in four phase 3 trials, with average weight loss in some groups approaching what is usually seen after bariatric surgery. But it is not approved anywhere. Lilly has said it will file for US approval in the first quarter of 2027, after finishing its manufacturing data package. In the meantime, an unregulated market in so-called research peptides has grown up around the name, and both the FDA and Lilly have moved against it.

This explainer covers what retatrutide is, what the trials have shown so far, where the regulatory filing stands, and why the products sold online under its name are a separate and riskier thing.

What retatrutide is

Retatrutide (development code LY3437943) is a single peptide built to activate three hormone receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. That makes it a "triple agonist", one step beyond the drugs already on the market. Semaglutide (Wegovy, Ozempic) acts on the GLP-1 receptor alone, and tirzepatide (Zepbound, Mounjaro) acts on GLP-1 and GIP receptors.

Each receptor contributes something different. GLP-1 signalling slows gastric emptying, increases insulin release after meals and acts on appetite centres in the brain. GIP signalling adds to the insulin response and appears to improve the tolerability and size of the weight effect when combined with GLP-1 agonism. The glucagon receptor is the new element. Glucagon normally raises blood sugar, which sounds like the wrong direction for a metabolic drug, but it also increases energy expenditure and drives fat oxidation in the liver. The design bet is that GLP-1 and GIP activity will hold blood glucose in check while the glucagon component adds extra calorie burn and liver-fat reduction on top of reduced food intake.

That bet showed early promise in a phase 2 trial published in the New England Journal of Medicine in 2023, where the 12 mg dose produced an average weight loss of 24.2% at 48 weeks in adults with obesity. The phase 3 programme, called TRIUMPH, was designed to test whether those results held up in larger and more varied populations over longer periods.

What the phase 3 trials have shown

Lilly has reported topline results from four TRIUMPH trials. All were placebo-controlled, and all were announced by press release; full peer-reviewed publications are still to come for most of them, so the figures below may be refined.

TRIUMPH-4: obesity with knee osteoarthritis

The first phase 3 readout, in December 2025, enrolled adults with obesity or overweight and knee osteoarthritis, without diabetes. At 68 weeks, participants on 12 mg lost an average of 28.7% of body weight and those on 9 mg lost 26.4%, compared with 2.1% on placebo. Knee pain on the WOMAC scale fell by up to about 4.5 points from a baseline of around six, roughly a 76% improvement. About 18% of people on the highest dose stopped treatment because of side effects, against about 4% on placebo, and Lilly noted that adverse-event discontinuations were higher in people with a lower starting BMI.

TRIUMPH-1: obesity without diabetes

TRIUMPH-1 is the main registration trial, with 2,339 adults with obesity or overweight plus at least one weight-related condition, randomised to 4 mg, 9 mg, 12 mg or placebo for 80 weeks. Lilly reported the results in May 2026, and two different headline numbers have circulated. Both are correct; they answer different questions.

• The efficacy estimand, which estimates the effect in people who stayed on their assigned treatment, gave an average loss of 28.3% on 12 mg, 25.9% on 9 mg and 19.0% on 4 mg.
• The treatment-regimen estimand, which counts everyone randomised regardless of whether they stopped the drug, gave 25.0%, 23.7% and 17.6% respectively, against 3.9% on placebo.

The second figure is closer to what a clinic might see in practice, where some patients stop treatment. Much of the "30% weight loss" coverage refers to a separate pre-specified extension: 532 participants with a starting BMI of 35 or more who tolerated treatment continued to 104 weeks, and those on 12 mg had lost an average of 30.3% of body weight at that point.

TRIUMPH-2 and TRIUMPH-3: diabetes and heart disease

In July 2026 Lilly reported two more trials in harder-to-treat groups. TRIUMPH-2 enrolled 1,152 adults with type 2 diabetes and obesity or overweight. At 80 weeks, weight fell by 12.7%, 19.1% and 20.8% on the 4, 9 and 12 mg doses, versus 4.0% on placebo (efficacy estimand), and HbA1c fell by 1.4 to 1.6 percentage points from a baseline of 7.7%. People with diabetes typically lose less weight on incretin drugs, so the smaller numbers were expected.

TRIUMPH-3 enrolled 1,949 adults with severe obesity (BMI 35 or above) and established cardiovascular disease. Weight loss at 80 weeks was 21.6% on 9 mg and 22.6% on 12 mg, against 3.2% on placebo. Triglycerides, non-HDL cholesterol, systolic blood pressure and the inflammatory marker hsCRP all fell.

Safety and open questions

The side-effect profile looks broadly like that of other incretin drugs but stronger at higher doses. In TRIUMPH-1, nausea affected 42.4% of people on 12 mg (14.8% on placebo), diarrhoea 32.0%, constipation 26.1% and vomiting 25.3%. Discontinuation because of adverse events was 11.3% on 12 mg versus 4.9% on placebo. Lilly describes most of these events as mild to moderate and largely resolving during treatment.

One signal is more specific to retatrutide: dysesthesia, an abnormal skin sensation such as tingling or burning. It was reported in up to 20.9% of participants on 12 mg in TRIUMPH-4, and in 6% to 7% at the higher doses in TRIUMPH-2 and TRIUMPH-3, compared with about 1% on placebo. Its mechanism and long-term significance are not yet clear.

Cardiovascular data remain inconclusive. In TRIUMPH-3 there were 27 major adverse cardiovascular events (MACE-3) on retatrutide and 23 on placebo, a hazard ratio of 1.12 with a confidence interval of 0.64 to 1.96. A broader five-component measure leaned the other way (hazard ratio 0.82, interval 0.55 to 1.22). Events were rarer than expected in both arms, and the trial was not designed to show a heart benefit or harm. One analyst called the sample too small and the follow-up too short to draw firm conclusions. A dedicated cardiovascular and renal outcomes trial is part of the wider TRIUMPH programme.

Where the FDA filing stands

Lilly had earlier signalled that retatrutide could be submitted by the end of 2026. In July 2026 it said the clinical data package was complete, but that it needed more time to finish its chemistry, manufacturing and controls (CMC) data, the part of an application that shows the product can be made consistently at scale. It now plans to file a Biologics License Application in the US in the first quarter of 2027, with submissions elsewhere for obesity, knee osteoarthritis pain and obstructive sleep apnea.

A standard FDA review usually takes about 10 to 12 months from filing, so if the application is accepted and goes smoothly, a decision would be expected in late 2027 or early 2028. That is an estimate based on typical timelines, not a company commitment, and priority review or a request for more data would change it.

The counterfeit and "research peptide" problem

Search interest in retatrutide has risen sharply over the past year, and much of it is commercial: people searching for prices, doses and where to buy. Because Lilly does not sell the drug, anything sold as retatrutide today did not come from a regulated supply chain.

Most of these products are marketed as "research peptides", sold as freeze-dried powder in vials labelled "for research use only" or "not for human consumption", often with dosing guides alongside. The FDA's position is that the label does not change what the product is. In warning letters going back to late 2024, and in a further round in September 2025, it treated retatrutide sold this way, or compounded by pharmacies, as an unapproved new drug. Retatrutide is not on the lists of substances pharmacies may use for compounding. In June 2026 the agency named retatrutide and Novo Nordisk's investigational cagrilintide specifically, saying neither is approved for any condition or usable in compounding, and warning consumers that such products are of unknown quality and may be harmful.

Lilly has gone further. On 12 August 2026 it filed six federal lawsuits in California and Texas against a med spa, a compounding pharmacy and four research-peptide sellers, seeking injunctions and the return of profits. The company says it has referred more than 200 individuals and entities to regulators and law enforcement and reported more than 14,000 listings and posts in over 100 countries. The allegations have not yet been tested in court.

The clinical risks are practical rather than theoretical. A vial bought this way may contain the wrong amount of peptide, a different peptide, synthesis by-products or bacterial contamination, and there is no batch testing, sterility assurance or traceability to check. People self-injecting also lack the gradual dose escalation used in the trials, which is a large part of how gastrointestinal side effects were managed. And none of the safety data above applies to an unverified product.

What to watch

• Full publications of TRIUMPH-1 to TRIUMPH-4, including detailed dysesthesia and body-composition data.
• The BLA filing in the first quarter of 2027, and whether the FDA grants standard or priority review.
• Remaining TRIUMPH trials in sleep apnea, low back pain, fatty liver disease and cardiovascular and renal outcomes.
• Enforcement: further FDA action against online sellers and the progress of Lilly's lawsuits.

This article is for information only and is not medical advice. Treatment decisions should be made with a qualified clinician.

Sources: Eli Lilly (TRIUMPH-2/3 release); Eli Lilly (TRIUMPH-1 release, via BioSpace); BioPharma Dive; AJMC; The Pharmaceutical Journal; Pharmaceutical Executive; pharmaphorum; Healio; FDA warning letter (Summit Research Peptides); NEJM (phase 2, 2023)